Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

111 results about "Amyloid beta" patented technology

Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold.

Pharmaceutical composition for prevention or treatment of degenerative brain diseases comprising selexipag

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising selexipag or a pharmaceutically acceptable salt thereof as an active ingredient. Selexipag inhibits the expression and production of pro-inflammatory or inflammatory cytokines in brain tissue, inhibits the activity of microglia or astrocytes, inhibits NLRP3 inflammasome activity and CDK6 expression, reduces amyloid plaques, increases the expression of the amyloid beta-degrading enzyme IDE, and inhibits the hyperphosphorylation of tau protein and the expression of tau kinase, and thus can be effectively used as a novel therapeutic agent for the prevention or treatment of degenerative brain diseases, cognitive disorders, learning disabilities, or memory disorders.
Owner:DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Engineered Chimeric Antigen Receptor (CAR) Microglia-Like Cells for the Treatment of Neurodegenerative Disorders

The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Aβ) and / or Tau. In certain embodiments, the CARs do not comprise an intracellular domain. Methods of treatment are also disclosed herein.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Computer-operated prediction of amyloid-related imaging abnormalities

PendingCN119173951AImage enhancementChemical property predictionHigh signal intensityInversion recovery
The present application identifies a dose of an active ingredient in therapy provided or considered to be provided to a subject. The level of localized amyloid beta is predicted based on the dose of the active ingredient. The severity of amyloid related imaging anomalies (ARIA) (ARIA-E) exhibiting high signal strength on T2 weighted liquid decay inversion recovery (FLAIR) images is predicted based on the predicted removal of local beta amyloid, wherein predicting the severity of ARIA-E includes predicting the degree of vascular wall disorder. And outputting a result corresponding to the predicted ARIA-E severity degree.
Owner:F HOFFMANN LA ROCHE & CO AG

Extracellular vesicle drug delivery system, preparation method thereof and application of extracellular vesicle drug delivery system in treatment of Alzheimer's disease

PendingCN121825870AOrganic active ingredientsCell dissociation methodsAmyloid betaMicroglial cell activation
The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

CRISPR / Cas12a-based electrochemical biosensor as well as preparation method, test method and application thereof

The invention relates to the technical field of electrochemical analysis and detection, in particular to an electrochemical biosensor based on CRISPR / Cas12a as well as a preparation method, a detection method and application of the electrochemical biosensor. An electrochemical biosensor based on CRISPR / Cas12a comprises a Cas12a-crRNA detection system, an APT-ActDNA adaptation system and an electrochemical aptamer sensor, and when a target analyte exists, the Cas12a-crRNA detection system and the APT-ActDNA adaptation system are matched with each other to react with the target analyte, so that the electrochemical aptamer sensor generates an electrochemical signal. According to the technical scheme, the problems of specific recognition and detection of amyloid beta peptide (Abeta) in a complex biological sample are solved, the preparation method is simple, the cost is low, and the detection method is high in sensitivity and accuracy.
Owner:ANHUI UNIV

Anti-amyloid beta antibodies and related compositions and methods thereof

Provided are anti-amyloid beta antibodies or antigen-binding fragments thereof, and chimeric antigen receptors (CARs), conjugates, and multi-specific antibodies that include the same. Also provided are methods of making and using the antibodies or antigen-binding fragments thereof, as well as engineered cells expressing or containing the same.
Owner:BOARD OF RGT UNIV OF NEBRASKA

Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.
Owner:SHIMADZU CORP

Compounds, systems, and techniques for removal of peripheral amyloid beta peptide with albumin binding competitors

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.
Owner:FRESENIUS MEDICAL CARE HOLDINGS INC

Use of methylated peptide as therapeutic agent for degenerative brain diseases

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.
Owner:KINE SCI CO LTD

Anti-amyloid beta fibril / oligomer antibodies and uses thereof

The present disclosure provides anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that preferentially bind to soluble amyloid [beta] fibrils / oligomers and trigger ADPC in microglial cells; anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that reduce soluble amyloid [beta] fibril / oligomer levels and insoluble amyloid [beta] plaques in brain tissue; and the use of anti-A [beta] fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with A [beta] protein aggregation, in particular Alzheimer's Disease (AD).
Owner:MABWELL THERAPEUTICS INC

Application of Yangxue oral liquid in preparing neuroprotective drugs for Alzheimer's disease and / or Parkinson's disease

The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease, and belongs to the field of biopharmaceutical technology. The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease. By verifying the effects of Yangxue Oral Liquid on the amyloid beta-induced neuronal apoptosis model, the cobalt chloride-induced SH‑SY5Y cell hypoxia model, and the LPS-induced SH‑SY5Y cell inflammation model, the results showed that Yangxue Oral Liquid has a neuroprotective effect against Alzheimer's disease and / or Parkinson's disease. Therefore, the application provided by the present invention provides a new means for neuroprotection against Alzheimer's disease and / or Parkinson's disease.
Owner:HUBEI FENGHUANG BAIYUNSHAN PHARM CO LTD

Novel molecule for diagnosis

To provide a novel amyloid beta (A beta) binding molecule, especially an amyloid beta antibody or an antigen-binding fragment thereof, and / or use of them.SOLUTION: There is provided an amyloid beta binding antibody including: VH-CDR1 including a specific amino acid sequence, VH-CDR2 including a specific amino acid sequence, VH-CDR3 including a specific amino acid sequence, VL-CDR1 including a specific amino acid sequence, VL-CDR2 including a specific amino acid sequence, and VL-CDR3 including a specific amino acid sequence; or an antigen-binding fragment thereof. In one embodiment, independently of an amyloid beta peptide or a three-dimensional structure states of a seed, an amyloid beta binding antibody or an antigen binding fragment thereof selectively binds to an amyloid beta peptide or seed in a solution, or captures the amyloid beta peptide or seed.SELECTED DRAWING: None
Owner:AC IMMUNE SA

Catalytic antibodies and methods of use thereof

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.
Owner:AB STUDIO INC

Composition for predicting clinical stage of alzheimer's disease and kit using the same

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY

A combination of scyllo-inositol and n-acetyl cysteine and related compounds

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.
Owner:EIRGEN PHARMA LTD

Vaccination against the amyloid-beta 40 peptide

The present invention refers to a vaccine composition comprising amyloid beta 33-40 (Aβ33-40) peptide with an additional cysteine in the N-terminal end (CysAβ33-40) conjugated with the carrier protein keyhole limpet hemocyanin (KLH) using as the crosslinking agent the maleimidobutiric acid N-hydroxysuccinimide ester (SM) and aluminium hydroxide gel as adjuvant for the treatment and / or prevention of cerebral amyloid angiopathy (CAA), the method comprising administering a therapeutically effective amount of said vaccine composition comprising to a patient in need thereof.
Owner:ARACLON BIOTECH

ANTIBODIES BINDING TO A BETA pE3

An antibody or antigen-binding fragment thereof that binds to A [beta] pE3, i.e., to the N-terminal truncated and pyroglutamic acid modified form of amyloid [beta] (A [beta]), and therapeutic and diagnostic uses thereof are disclosed.
Owner:BIOSCOPE

Intracellular domain of AXL or fragment derived therefrom, and use for regulating autophagy using same

The present invention relates to an intracellular domain of AXL or a fragment derived therefrom, and a use for regulating autophagy using same, wherein the intracellular domain of AXL or the fragment derived therefrom can regulate a selective autophagy pathway in response to an intracellular amyloid beta signal.
Owner:INST FOR BASIC SCI

Pharmaceutical composition containing neprilysin-overexpressing stem cell, conditioned medium thereof, and exosome isolated therefrom as active ingredient for prevention or treatment of cognitive impairment

Disclosed herein is a pharmaceutical composition containing a neprilysin-overexpressing stem cell, a conditioned medium thereof, and an exosome isolated therefrom as an active ingredient for prevention or treatment of cognitive impairment. Having the functions of protecting nerve cells, inhibiting the accumulation of amyloid beta, known as a cause of cognitive impairment-related disease in animal models, increasing an expression level of acetyl choline, and improving cognitive functions in animal models, the neprilysin-overexpressing stem cells, the conditioned medium thereof, or the exosomes isolated therefrom according to the present disclosure can find advantageous applications in treating cognitive impairment.
Owner:DESIGNED CELLS CO LTD

Vaccine for treating anti a bata

To provide a high immunogenicity anti Aβ vaccine while maintaining an excellent safety profile.SOLUTION: A liposome vaccine composition includes a peptide antigen derived from β-amyloid (Aβ) presented on a surface of a liposome. The vaccine composition further includes a peptide including a universal T-cell epitope encapsulated into the liposome. The vaccine composition also may form a part of the liposome, and includes an adjuvant that may be at least partially presented on the surface of the liposome. The vaccine compositions are used for treating or preventing a disease or a condition related to amyloid beta, or symptoms characterized in loss of cognitive memory ability of a subject or a condition related thereto, inducing protective immune response to the symptom, or alleviating the symptoms. The vaccine composition may be provided as a kit. A related method for producing a liposome vaccine composition is also provided.SELECTED DRAWING: None
Owner:AC IMMUNE SA

Animal model for rapid attack of Alzheimer's disease amyloid beta plaque lesion

PendingCN121263062ACompounds screening/testingVectorsAmyloid betaAmyloid precursor protein
Provided herein are compositions comprising a nucleic acid encoding an amyloid-beta precursor protein and / or a nucleic acid encoding premature protein-1, cells comprising these compositions, animals comprising these compositions, methods of making these cells and animals, methods of modeling Alzheimer's disease, and methods of preparing such cells and animals. A method of assessing a treatment candidate for treating or ameliorating a symptom or phenotype of Alzheimer's disease, and a method of assessing a treatment candidate for preventing or preventing a symptom or phenotype of Alzheimer's disease.
Owner:REGENERON PHARMACEUTICALS INC

Use of lecanemab in ophthalmological conditions

This disclosure related to a method of preventing or treating an amyloid- associated retinal disease in an individual in need thereof, the method comprises administering to the individual a therapeutically effective amount of an antibody with high affinity and specificity for amyloid beta (Abeta) oligomers, Abeta protofibrils or combination thereof.
Owner:GALIMEDIX THERAPEUTICS INC

Antibody that binds to AβpE3

Disclosed are antibodies or antigen-binding fragments thereof that bind to AβpE3, an N-terminally truncated, pyroglutamic acid-modified form of amyloid beta (Aβ), and their therapeutic and diagnostic uses.
Owner:BIOARCTIC AB

Relatively insufficient-supply amyloid beta aggregation inhibitors for improving detoxification effects

Provided herein is a method of treating or preventing protein misfolding and deposition diseases in a subject by administering to the subject a low dose of Compound (1). Also provided herein is a method of reversing or preventing the toxic effect of the misfolded and aggregated protein amyloid beta by using a relatively insufficient supply (reverse stoichiometric) compound (1) to achieve a stronger detoxification effect. The invention further provides the dosage and the application mode of the composition.
Owner:GALIMEDIX THERAPEUTICS INC

Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease

Binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided.
Owner:SANOFI SA(FR) +1

Method for diagnosing early and classifying stages of alzheimer's disease and determining amyloid beta accumulation in brain by using tau protein-derived phosphorylated peptide

A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Owner:GWANGJU INST OF SCI & TECH +2